approach
Anchor with clinical evidence
Therapeutic development typically originates from cellular and animal models, leading to a remarkable attrition rate due to the ‘translational’ gap between laboratory findings and patients. Immetas’ strategy begins with clinical data, including from human genetic disorders and clinical trials involving the relevant targets; by matching molecular profiling of the target pathways with disease signatures; and by applying statistical algorithms to explore disease pathology and outcomes. Integrating such clinical data at the front end of drug discovery is designed to mitigate this development risk.
Dissect Mechanism of Action
Innovative medicines to address unmet medical needs rely on breakthroughs in understanding disease mechanisms and targeting unexplored (or underexplored) pathways and targets. Emerging research that molecular pathways driving both cellular aging and age-related diseases converge around chronic inflammation is creating a new set of opportunities to treat cancer and other serious diseases. Guided by the co-founders’ rich experience in aging and inflammation, Immetas is well positioned to capitalize on these new advances and enable the design of superior, well-differentiated products that can be developed rapidly to IND and clinical proof of concept.
Clinically-led and MoA-guided Drug Design
Immetas’ approach to targeting chronic inflammation provides opportunities for a broad range of therapeutic opportunities and interventions in the form of either small or large molecules and systemic or local delivery.